Parichart Permpikul

Dr. Parichart Permpikul

Department of Transfusion medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 1995 in The American Journal of Medicine
Verified
Journal Article
Closed access
WAWilliam R. Auger
William R. Auger
Parichart PermpikulParichart Permpikul
Parichart Permpikul
KMKenneth M. Moser
Kenneth M. Moser

1 April 2017 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
ENEgarit Noulsri
Egarit Noulsri
PUPrapaporn Udomwinijsilp
Prapaporn Udomwinijsilp
SLSurada Lerdwana
Surada Lerdwana
VCViroje Chongkolwatana
Viroje Chongkolwatana
Parichart PermpikulParichart Permpikul
Parichart Permpikul

9 June 2010 in Archives of Virology
Verified
Journal Article
Closed access
PDF file
YMYuwarat Monteerarat
Yuwarat Monteerarat
SSSaori Sakabe
Saori Sakabe
SNSomying Ngamurulert
Somying Ngamurulert
SSSirawat Srichatraphimuk
Sirawat Srichatraphimuk
WJWasana Jiamtom
Wasana Jiamtom
PAPrasert Auewarakul
Prasert Auewarakul

1 October 2012 in AIDS Research and Human Retroviruses
Verified
Journal Article
Closed access
SASilawun Ampol
Silawun Ampol
KPKovit Pattanapanyasat
Kovit Pattanapanyasat
RSRuengpung Sutthent
Ruengpung Sutthent
Parichart PermpikulParichart Permpikul
Parichart Permpikul
WKWannee Kantakamalakul
Wannee Kantakamalakul
The antibody-dependent cell-mediated cytotoxicity (ADCC) mechanism involves both innate and adaptive immune systems. While a number of epitope mapping studies of neutralizing (Nt) antibodies and cytotoxic T lymphocyte (CTL) against a variety of HIV-1 clades have been reported, there has been a paucity of similar studies aimed at identifying epitopes of ADCC-inducing antibodies. Herein we screened 35 sera from HIV-1 CRF01_AE-infected blood donors for ADCC antibody activity against gp120 utilizing an EGFP-CEM-NK r flow cytometric assay. Eighteen sera with high ADCC antibody activity were then comprehensively examined for ADCC antibody epitopes using the HIV-1 subtype CRF01_AE TH023 gp120 peptide set consisting of 126 peptides of 15 amino acids in length, overlapping by 11 amino acids. This peptide set was divided into five pools (E1–E5). Each positive peptide pool was further investigated for fine epitope mapping of ADCC antibody activity using a 5 by 5 peptide matrix format. Interestingly, six and three peptides from peptide pools E1 and E2, respectively, responded to at least 33.33% of the tested sera. These nine common ADCC epitopes were localized to the C1 and V2 region of gp120. Furthermore, 5/9 epitopes were also shown to serve as full or partial Nt antibody targets for HIV-1 subtypes B and CRF01_AE. We submit these data on epitope mapping of ADCC or dual ADCC-Nt antibodies against HIV-1 gp120 that should be considered in the formulation of vaccines against HIV-1.

1 November 2006
Verified
Journal Article
Closed access
TTTawesak Tanwandee
Tawesak Tanwandee
TPTeerha Piratvisuth
Teerha Piratvisuth
KPKannilka Phornphutkul
Kannilka Phornphutkul
PMPisaln Mairiang
Pisaln Mairiang
Parichart PermpikulParichart Permpikul
Parichart Permpikul
YPYong Poovorawan
Yong Poovorawan